Radical Prostatectomy With and Without Neoadjuvant Chemohormonal Pretreatment for High-Risk Localized Prostate Cancer: A Comparative Propensity Score Matched Analysis

Shintaro Narita, Taketoshi Nara, Sohei Kanda, Kazuyuki Numakura, Mitsuru Saito, Takamitsu Inoue, Shigeru Satoh, Hiroshi Nanjo, Norihiko Tsuchiya, Koji Mitsuzuka, Takuya Koie, Sadafumi Kawamura, Chikara Ohyama, Tatsuo Tochigi, Yoichi Arai, Tomonori Habuchi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: To investigate the clinical outcomes in patients with high-risk prostate cancer (PCa) treated with neoadjuvant chemohormonal therapy (NCHT) before radical prostatectomy (RP). Patients and Methods: Our NCHT protocol involved complete androgen blockade followed by 6 cycles of docetaxel (30 mg/m 2 ) plus estramustine phosphate (560 mg). NCHT was provided to 60 patients with PCa before RP, and we compared the clinical and pathologic outcomes with those of 349 patients with high-risk PCa who underwent RP alone using propensity score matching. The data for those who underwent RP alone were obtained from the Michinoku Japan Urological Cancer Study Group database. Results: In the NCHT group, 10.0% experienced pathologic complete response, 3.3% had positive surgical margins, and 13.3% developed severe complications (Clavien-Dindo grade III or higher) after RP. The median follow-up duration was 42.5 months, and the 5-year biochemical recurrence (BCR)-free survival was 60.1%. In multivariate analysis, pN+ was an independent prognostic factor for BCR (hazard ratio = 5.251, 95%CI 1.300-21.201; P =.020). In propensity score matching, the BCR rate in the NCHT group was significantly lower than that in the RP alone group (P =.021). In subgroup analyses, the BCR rate in patients with a single high-risk factor was significantly lower in the NCHT group than in the RP-alone group (P =.027). Conclusion: NCHT before RP can reduce the risk of BCR in patients with high-risk PCa, particularly if a single high-risk factor is present. However, the potential for perioperative complications should be considered.

Original languageEnglish
Pages (from-to)e113-e122
JournalClinical Genitourinary Cancer
Volume17
Issue number1
DOIs
Publication statusPublished - 2019 Feb

Keywords

  • Combined androgen blockade
  • Docetaxel
  • Estramustine phosphate
  • Neoadjuvant chemotherapy
  • Prostatectomy

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint Dive into the research topics of 'Radical Prostatectomy With and Without Neoadjuvant Chemohormonal Pretreatment for High-Risk Localized Prostate Cancer: A Comparative Propensity Score Matched Analysis'. Together they form a unique fingerprint.

  • Cite this

    Narita, S., Nara, T., Kanda, S., Numakura, K., Saito, M., Inoue, T., Satoh, S., Nanjo, H., Tsuchiya, N., Mitsuzuka, K., Koie, T., Kawamura, S., Ohyama, C., Tochigi, T., Arai, Y., & Habuchi, T. (2019). Radical Prostatectomy With and Without Neoadjuvant Chemohormonal Pretreatment for High-Risk Localized Prostate Cancer: A Comparative Propensity Score Matched Analysis. Clinical Genitourinary Cancer, 17(1), e113-e122. https://doi.org/10.1016/j.clgc.2018.09.019